Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Paying users zone. Data is hidden behind: .

  • Get 1-month access to Regeneron Pharmaceuticals Inc. for $15.99, or

  • get full access to the entire website for at least 3 months from $49.99.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey

This is a one-time payment. There is no automatic renewal.

Cash Flow Statement

Beginner level

The cash flow statement provides information about a company’s cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company’s balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Regeneron Pharmaceuticals Inc., consolidated cash flow statement

US$ in thousands

Microsoft Excel LibreOffice Calc
12 months ended: Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Net income
Depreciation and amortization
Non-cash compensation expense
Other non-cash items, net
Deferred taxes
(Increase) decrease in Sanofi, Bayer, and trade accounts receivable
(Increase) decrease in inventories
(Increase) decrease in prepaid expenses and other assets
Increase (decrease) in deferred revenue
Increase (decrease) in accounts payable, accrued expenses, and other liabilities
Changes in assets and liabilities
Adjustments to reconcile net income to net cash provided by operating activities
Net cash provided by operating activities
Purchases of marketable and other securities
Sales or maturities of marketable securities
Capital expenditures
Other
Net cash used in investing activities
Proceeds in connection with finance lease liabilities
Payments in connection with finance lease liabilities
Repayments of convertible senior notes
Payments in connection with reduction of outstanding warrants
Proceeds from issuance of Common Stock
Payments in connection with Common Stock tendered for employee tax obligations
Repurchases of Common Stock
Excess tax benefit from stock-based compensation
Net cash used in financing activities
Net increase (decrease) in cash, cash equivalents, and restricted cash
Cash, cash equivalents, and restricted cash at beginning of period
Cash, cash equivalents, and restricted cash at end of period

Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).

Cash flow statement item Description The company
Net cash provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Regeneron Pharmaceuticals Inc.’s net cash provided by operating activities increased from 2017 to 2018 and from 2018 to 2019.
Net cash used in investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Regeneron Pharmaceuticals Inc.’s net cash used in investing activities decreased from 2017 to 2018 and from 2018 to 2019.
Net cash used in financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Regeneron Pharmaceuticals Inc.’s net cash used in financing activities decreased from 2017 to 2018 and from 2018 to 2019.